

**Carbaglu (carglumic acid)**  
**Effective 12/01/2020**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
<b>Specialty Limitations</b>	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

### Overview

Carbaglu is used for the adjunctive treatment of acute hyperammonemia and maintenance therapy of chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) in adult and pediatric patients

### Coverage Guidelines

Authorization may be granted for members who are currently receiving treatment with Carbaglu, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

### OR

Authorization may be granted when one of the following criteria is met:

1. Diagnosis is hyperammonemia due to the N-acetylglutamate synthetase (NAGS) deficiency

### Continuation of Therapy

Reauthorization may be granted when improvement per physician assessment/evaluation and documentation of improved and/or normalized blood ammonia levels for age is received.

### Limitations

1. Initial approvals will be granted for 12 months.
2. Reauthorizations will be granted for 36 months.

### Appendix

<b>Recommended Dosing:</b>	
Acute hyperammonemia (adult & pediatric)	Initial: 100 to 250 mg/kg/day
Chronic hyperammonemia (adult & pediatric)	Initial: ≤ 100mg/kg/day

	<p><u>Maintenance</u>: dose titrated to the normal plasma ammonia level for age (generally less than 100 mg/kg/day); total daily dose should be divided into 2 to 4 doses and rounded to the nearest 100 mg.</p>
<p>Note: tablets should not be swallowed whole or crushed. Please refer to the prescribing information for adult and pediatric oral administration recommendations as well as nasogastric tube administration directions.</p>	

**Pharmacist’s Notes:**

1. Any episode of acute symptomatic hyperammonemia should be treated as a life-threatening emergency & treatment may require hemodialysis in some instances.
2. The management of hyperammonemia due to NAGS deficiency should be done in coordination with medical personnel experienced in metabolic disorders.
3. Plasma ammonia levels should also be maintained within normal range for age through individual dose adjustment.
4. During acute hyperammonemia episodes, protein restrictions and hyper-caloric intake is recommended to block ammonia-generating catabolic pathways. Protein intake can subsequently be increased when ammonia levels have normalized.

**References**

1. Carbaglu (carglumic acid) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases Inc; December 2019
2. Lee B. Clinical features and diagnosis of urea cycle disorders. In: Firth HV (Ed). UpToDate [database on the Internet]. Waltham (MA): UpToDate; 2014. Available from: <http://www.uptodate.com/upt/index.do>.
3. NAGS deficiency [press release on the Internet]. Paris (France): Orphan Europe SARL; 2007 Mar 22. Available from: <http://www.orphan-europe.com/Data/ModuleGestionDeContenu/03-Diseases/Hyperammonaemia/16.asp>.
4. Carglumic acid. Cross-Discipline Team Leader Review [monograph on the Internet]. Rockville (MD): Center for Drug Evaluation and Research; 2010. Available frfentanom: [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2010/022562s000crossr.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022562s000crossr.pdf).
5. Gessler P, Buchal P, Schwenk HU, Wermuth B. Favourable long-term outcome after immediate treatment of neonatal hyperammonemia due to N-acetylglutamate synthase deficiency. Eur J Pediatr. 2010;169:197-199.
6. N-acetylglutamate synthetase deficiency. National Organization of Rare Diseases (NORD). 2014. Available at: <http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/313/viewFullReport>
7. Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med 2011; 4:21
8. Lee B, Diaz GA, Rhead W, et al. Glutamine and hyperammonemic crises in patients with urea cycle disorders. Mol Genet Metab 2016; 117:27

**Review History**

- 06/25/2012 – Reviewed
- 06/24/2013 – Reviewed
- 06/23/2014 – Reviewed
- 06/22/2015 – Reviewed



06/27/2016 – Reviewed

06/26/2017 – Reviewed

06/25/2018 – Reviewed

06/19/2019 – Reviewed

07/22/2020 – Reviewed and updated July P&T Mtg; added started and stabilized statement

09/16/2020 – Reviewed and updated Sept P&T Mtg; removed specialist requirement; references updated.

Effective 12/01/2020.

